Zobrazeno 1 - 10
of 24
pro vyhledávání: '"David Perna-Barrull"'
Autor:
Laia Gomez-Muñoz, David Perna-Barrull, Josep M. Caroz-Armayones, Marta Murillo, Silvia Rodriguez-Fernandez, Aina Valls, Federico Vazquez, Jacobo Perez, Raquel Corripio, Luis Castaño, Joan Bel, Marta Vives-Pi
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/d946255df1a24637a2d10b2a7920b4a5
Autor:
Laia Gomez-Muñoz, David Perna-Barrull, Adrian Villalba, Silvia Rodriguez-Fernandez, Rosa-Maria Ampudia, Aina Teniente-Serra, Federico Vazquez, Marta Murillo, Jacobo Perez, Raquel Corripio, Joan Bel, Marta Vives-Pi
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/fe4e09f9ddbe47b094d955e42bde0dbb
Autor:
Laia Gomez-Muñoz, David Perna-Barrull, Marta Murillo, Maria Pilar Armengol, Marta Alcalde, Marti Catala, Silvia Rodriguez-Fernandez, Sergi Sunye, Aina Valls, Jacobo Perez, Raquel Corripio, Marta Vives-Pi
Publikováno v:
Non-Coding RNA, Vol 9, Iss 2, p 17 (2023)
The partial remission (PR) phase of type 1 diabetes (T1D) is an underexplored period characterized by endogenous insulin production and downmodulated autoimmunity. To comprehend the mechanisms behind this transitory phase and develop precision medici
Externí odkaz:
https://doaj.org/article/36f893f2ab0c4653bb40a299f1f66a96
Autor:
Laia Gomez-Muñoz, David Perna-Barrull, Josep M. Caroz-Armayones, Marta Murillo, Silvia Rodriguez-Fernandez, Aina Valls, Federico Vazquez, Jacobo Perez, Raquel Corripio, Luis Castaño, Joan Bel, Marta Vives-Pi
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The partial remission (PR) phase, a period experienced by most patients with type 1 diabetes (T1D) soon after diagnosis, is characterized by low insulin requirements and improved glycemic control. Given the great potential of this phase as a therapeu
Externí odkaz:
https://doaj.org/article/583b883237ef4d5a90367b7a3cab653f
Autor:
Adrian Villalba, Silvia Rodriguez-Fernandez, Rosa-Maria Ampudia, Mary Cano-Sarabia, David Perna-Barrull, Cesc Bertran-Cobo, Clara Ehrenberg, Daniel Maspoch, Marta Vives-Pi
Publikováno v:
Artificial Cells, Nanomedicine, and Biotechnology, Vol 48, Iss 1, Pp 77-83 (2020)
Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of insulin-producing cells. Due to the ability of apoptotic cells clearance to induce tolerance, we previously generated liposomes rich in phophatidylserine (PS) –a feature of
Externí odkaz:
https://doaj.org/article/b7b735d04d2b4ab7bf2aa7da1ed37f6b
Autor:
David Perna-Barrull, Marta Murillo, Nati Real, Laia Gomez-Muñoz, Silvia Rodriguez-Fernandez, Joan Bel, Manel Puig-Domingo, Marta Vives-Pi
Publikováno v:
Journal of Diabetes Research, Vol 2022 (2022)
Background. Betamethasone, a glucocorticoid used to induce lung maturation when there is a risk of preterm delivery, can affect the immune system maturation and type 1 diabetes (T1D) incidence in the progeny. It has been described that prenatal betam
Externí odkaz:
https://doaj.org/article/afc39d22ac9949ae926c1b9f1f7d011f
Autor:
Laia Gomez-Muñoz, David Perna-Barrull, Adrian Villalba, Silvia Rodriguez-Fernandez, Rosa-Maria Ampudia, Aina Teniente-Serra, Federico Vazquez, Marta Murillo, Jacobo Perez, Raquel Corripio, Joan Bel, Marta Vives-Pi
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Type 1 diabetes (T1D) is a chronic metabolic disease characterized by the autoimmune destruction of β-cells in the pancreatic islets. T1D is preceded by islet-specific inflammation led by several immune cells. Among them, natural killer (NK) cells a
Externí odkaz:
https://doaj.org/article/bb88041d94bd41f4939c9e73c22b11b0
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Type 1 diabetes (T1D) is a multifactorial disease of unknown aetiology. Studies focusing on environment-related prenatal changes, which might have an influence on the development of T1D, are still missing. Drugs, such as betamethasone, are used durin
Externí odkaz:
https://doaj.org/article/4d486670021b42d4bd8133f64f147212
Autor:
Adrian Villalba, Silvia Rodriguez-Fernandez, David Perna-Barrull, Rosa-Maria Ampudia, Laia Gomez-Muñoz, Irma Pujol-Autonell, Eva Aguilera, Mireia Coma, Mary Cano-Sarabia, Federico Vázquez, Joan Verdaguer, Marta Vives-Pi
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin-producing β-cells. An ideal immunotherapy should combine the blockade of the autoimmune response with the recovery of functional target cell mass. With the aim to deve
Externí odkaz:
https://doaj.org/article/5559bcea26c84fd39f8be1bf28b3d832
Autor:
Silvia Rodriguez-Fernandez, Marta Murillo, Adrian Villalba, David Perna-Barrull, Mary Cano-Sarabia, Laia Gomez-Muñoz, Eva Aguilera, Daniel Maspoch, Federico Vazquez, Joan Bel, Marta Vives-Pi
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt
Externí odkaz:
https://doaj.org/article/19af0f58ed9f4b98a4e3dcd3fcc6abe0